What is Bacillus calmette‑guérin (BCG) intravesical treatment and how does it work for patients with non‑muscle‑invasive bladder cancer?

What is BCG Intravesical Treatment for Bladder Cancer Patients

BCG (Bacillus Calmette-Guérin) intravesical treatment is a live, attenuated bacterial immunotherapy instilled directly into the bladder through a catheter to prevent recurrence and progression of non-muscle invasive bladder cancer (NMIBC), particularly for high-risk disease. 1, 2

How BCG Works

BCG is a weakened strain of Mycobacterium bovis that triggers a powerful local immune response in the bladder wall. When instilled into the bladder, it stimulates the immune system to attack cancer cells by:

• Inducing secretion of proinflammatory cytokines 1
• Creating a systemic, nonspecific immunostimulatory response 1
• Activating local immune cells to recognize and destroy tumor cells 3

The exact mechanism remains incompletely understood, but this immune activation is what makes BCG superior to chemotherapy alone for preventing disease progression 1, 3.

Treatment Protocol

Standard Dosing Schedule

Induction phase: BCG is given once weekly for 6 weeks, followed by a 4-6 week rest period, with full reevaluation at 3 months after starting therapy 1.

Maintenance therapy is critical - this is the single most important factor in improving outcomes 4. The standard maintenance schedule involves:

• Weekly instillations for 3 weeks at 3,6, and 12 months after induction
• For high-risk NMIBC, additional maintenance at 18,24,30, and 36 months 5

The BCG preparation contains 1-8 × 10⁸ colony forming units per vial, reconstituted with sterile water immediately before use 2.

Who Should Receive BCG

BCG is the gold standard first-line treatment for high-risk NMIBC 1, 6. Based on current guidelines:

• High-risk patients: BCG with maintenance is mandatory 1
• Intermediate-risk patients with 3+ risk factors: BCG with 1 year maintenance should be considered 7
• Intermediate-risk with 1-2 risk factors: Intravesical chemotherapy is preferred; BCG only if prior chemotherapy was used 7
• Low-risk patients: Should NOT receive BCG due to unnecessary toxicity 6

What to Expect: Side Effects

Common Expected Effects (Not Complications)

Patients will experience flu-like symptoms lasting 48-72 hours after each instillation 1. This includes:

• Fever, anorexia, myalgia, and fatigue 2
• Dysuria (painful urination) - occurs in 60% of patients 1
• Bladder irritation mimicking a urinary tract infection 1

These symptoms are treatable in almost all cases and do not increase with cumulative doses 1.

Serious Complications Requiring Immediate Attention

Fever ≥103°F or acute inflammation persisting >2-3 days suggests active BCG infection - consult an infectious disease specialist immediately 2. Treatment with two or more antimycobacterial agents should be started without delay while awaiting cultures 2.

Rare but serious complications include:

• Disseminated BCG infection (fatal in 0.06-1.56 per million doses) 2
• BCG osteitis (bone infection) occurring 4 months to 2 years post-treatment 2
• BCG pneumonitis (lung inflammation) 8

Critical warning: BCG must NEVER be given intravenously, subcutaneously, intramuscularly, or intradermally - only intravesically (into the bladder) 2.

When BCG Fails

Approximately 60% of patients may not complete the full BCG course 9. BCG failure is defined as:

• BCG-unresponsive: Disease persists or recurs despite adequate BCG therapy
• BCG-refractory: Disease fails to respond to initial BCG treatment
• BCG-intolerant: Severe side effects prevent completion of therapy 4

For BCG-unresponsive disease, radical cystectomy (bladder removal) is the preferred treatment 1. However, alternatives for patients who cannot or will not undergo surgery include:

• Sequential gemcitabine and docetaxel intravesical chemotherapy 1
• Systemic pembrolizumab (FDA-approved) 1, 5
• Nadofaragene firadenovec 1, 5
• Clinical trial enrollment 7

Key Clinical Pitfalls to Avoid

1. Skipping maintenance therapy - induction alone is insufficient; maintenance is what prevents progression 4
2. Using BCG for low-risk disease - this causes unnecessary toxicity without benefit 6
3. Delaying cystectomy in truly BCG-refractory disease - these patients have very high progression risk 5, 6
4. Missing BCG infection signs - persistent fever or symptoms >2-3 days require immediate infectious disease consultation 2
5. Poor documentation of smoking status and reasons for discontinuation - this limits understanding of treatment failures 9

Efficacy Evidence

Multiple meta-analyses demonstrate BCG superiority over chemotherapy alone:

• Reduces recurrence risk in high-grade Ta and T1 tumors 1
• Decreases mortality by 23% compared to no BCG 1
• Superior to mitomycin C when maintenance is used 1

However, BCG with maintenance is superior to BCG without maintenance - this distinction is critical 4.